.
VTGN financial statements
* Numbers in thousands
Year |
2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
Capitalization * |
29 621 | 15 935 | 10 547 | 10 682 | 15 028 | 14 913 | 13 890 | 30 562 | 19 303 | 217 918 | 102 499 |
EV * |
32 827 | 20 639 | 17 464 | 24 875 | 14 671 | 12 049 | 3 568 | 17 522 | 18 321 | 118 528 | 118 528 |
Stock price $ |
40.2 | 17.6 | 9.6 | 8.1 | 8.5 | 1.98 | 1 | 1.07 | 0.44 | 2.53 | 1.19 |
Number of shares * |
737 | 905 | 1 099 | 1 319 | 1 768 | 7 532 | 13 890 | 28 562 | 43 870 | 86 134 | 86 134 |
EPS |
-16,57 | -14,23 | -2,70 | -10,53 | -26,71 | -1,36 | -1,03 | -0,86 | -0,47 | -0,21 | -0,21 |
Revenue * |
1 342 | 200 | 0 | 0 | 0 | 1 250 | 0 | 0 | 0 | 1 090 | 1 090 |
Net income * |
-12 210 | -12 887 | -2 968 | -13 886 | -47 221 | -10 256 | -14 346 | -24 590 | -20 774 | -17 934 | -17 934 |
Operating profit * |
-9 043 | -6 792 | -5 029 | -6 777 | -17 850 | -10 249 | -14 200 | -24 557 | -20 801 | -17 934 | -17 934 |
Total liabilities * |
6 047 | 13 438 | 13 064 | 20 813 | 3 967 | 3 096 | 4 362 | 6 937 | 11 502 | 16 303 | 16 303 |
Net debt * |
3 207 | 4 703 | 6 917 | 14 192 | -357 | -2 852 | -10 313 | -13 034 | 2 737 | -99 390 | -99 390 |
Total assets * |
342 | 882 | 264 | 270 | 990 | 3 712 | 11 278 | 14 012 | 5 772 | 108 281 | 108 281 |
Equity * |
-5 706 | -12 556 | -12 800 | -20 543 | -2 977 | 616 | 6 917 | 7 075 | -5 729 | 91 979 | 91 979 |
Cash and investments * |
81 | 638 | 0 | 70 | 429 | 2 921 | 10 378 | 13 100 | 1 355 | 103 108 | 103 108 |
Over the past 10 years, the maximum capitalization of VistaGen Therapeutics, Inc. is 217 918, the minimum is 10 547. Maximum net income 0, Minimum net income -47 221. The maximum price of VTGN shares is 40.2, the minimum price is 0.44.
.
VTGN valuation
Year |
2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-2,43 | -1,24 | -3,55 | -0,77 | -0,32 | -1,45 | -0,97 | -1,24 | -0,93 | -12,15 | -5,72 |
P/B |
-5,19 | -1,27 | -0,82 | -0,52 | -5,05 | 24,22 | 2,01 | 4,32 | -3,37 | 2,37 | 1,11 |
P/S |
22,07 | 79,52 | 0,00 | 0,00 | 0,00 | 11,93 | 0,00 | 0,00 | 0,00 | 200,02 | 94,08 |
E/P |
-41% | -81% | -28% | -130% | -314% | -69% | -103% | -80% | -108% | -8% | -18% |
P/FCF |
-8,23 | -4,43 | -4,94 | -3,86 | -3,11 | -1,99 | -1,53 | -2,08 | -1,23 | -17,65 | -8,30 |
.
VTGN profitability
Year |
2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
ROE |
214% | 103% | 23% | 68% | 1 586% | -1 665% | -207% | -348% | 363% | -20% | |
ROA |
-3 574% | -1 462% | -1 125% | -5 149% | -4 771% | -276% | -127% | -175% | -360% | -17% | |
ROIC |
318% | 443% | 102% | 40% | 2 218% | -437% | -145% | -219% | -693% | -17% |